An Observational Study of Patients With Dermatologic Disease
Part of paid clinical trials in Winston-Salem, North Carolina.
- Sponsor
- Target PharmaSolutions, Inc.
- Study ID
- NCT07748169
- Status
- Recruiting
Conditions
- Alopecia Areata
- Atopic Dermatitis
- Hidradenitis Suppurativa (HS)
- Vitiligo
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Study Details
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients. The study includes patients managed for DD of any etiology in usual clinical practice in the United States and addresses important clinical questions regarding the management of DD by collecting and analyzing data from patients at academic medical centers and community medical practices and/or data from providers who treat them.
Key Dates
- First listed
- Aug 5, 2026
- Start date
- Aug 1, 2026
- Status verified
- Jul 2026
- Primary completion
- Aug 3, 2041
- Completion
- Aug 3, 2041
Study Design
- Enrollment
- 2,000,000 participants (estimated)
Arms
- Arm: Disease CohortAdult patients and patients under the age of majority with a diagnosis of DD by ICD or other relevant healthcare code in the EHR interface.
- Arm: Engaged CohortAdult patients and patients under the age of majority diagnosed and managed for DD invited to participate OR HCPs who treat patients with these conditions. * Informed consent is required for all participants in an Engaged Cohort. * Willing to complete required Engaged Cohort activities.
Primary Outcome Measure
To assess safety and effectiveness of DD treatments and treatments for complications of any dermatologic disease [ Time Frame: 15 years ]
Central Contacts
- Lynda Lee Burch9842340268
- Danisha Devane9842340268
Locations (3)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Wake Forest University Health Science | Winston-Salem | North Carolina | 27157 | Steven Feldman, MD (PRINCIPAL_INVESTIGATOR) |
| University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Joel Gelfand, MD (PRINCIPAL_INVESTIGATOR) |
| Medical University of South Carolina | Charleston | South Carolina | 29407 | Lara Wine-Lee, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Winston-Salem, NC
Nationwide
By condition
By specialty
Related Studies
- Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis ResearchRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic DermatitisPHASE3 · Enrolling By Invitation · Eli Lilly and Company · Birmingham, Alabama
- A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic DermatitisPHASE2 · Recruiting · Pfizer · Birmingham, Alabama
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia AreataPHASE3 · Recruiting · AbbVie · Chula Vista, California